COPENHAGEN, Denmark, May 27, 2025 / Biotech Newswire / -- MC2 Therapeutics, a commercial-stage pharmaceutical company focused on topical therapies in inflammatory skin conditions, today announced the appointment of Trine Ahlgreen as Chief Executive Officer, marking a new chapter in the company’s journey to unlock the full global potential of its commercial asset, Wynzora® Cream, and to maximize the commercial potential of its formulation and drug delivery system, PAD Technology™.
With an extensive background spanning commercial leadership of global, regional and local pharmaceutical product launches, leadership of several successful cross-functional teams and business development across Europe, the US and Japan, Trine brings a breadth of experience to MC2 Therapeutics. With solid commercial foundation from large pharma and with a strong track record of strategic leadership and execution, Trine played key roles in several high-impact product launches at Novo Nordisk, including the launches of Ozempic®, Rybelsus® and the global cardiovascular indication launch for GLP-1. Most recently, at Swiss biotech Micreos Pharmaceuticals AG, Trine built the commercial and business development infrastructure focused on dermatology, forging valuable strategic partnerships across both pharma and OTC.
“MC2 Therapeutics has developed world-class innovation in topical therapies with a unique commitment to patient adherence and uncompromised efficacy”, said Trine Ahlgreen. “I’m honored to lead the next phase of the company’s growth, focused on realizing the full global commercial potential of Wynzora® Cream for plaque psoriasis, while exploring new opportunities through our proprietary PAD Technology™ formulation platform with selected partners”.
MC2 Therapeutics’ proprietary PAD Technology™ is an innovative formulation and delivery system that has been shown to significantly improve patient satisfaction and may support better treatment adherence - an essential factor in the management of chronic dermatologic conditions.
Wynzora® Cream, based on this advanced technology, has demonstrated strong clinical value and very successful uptake in key European markets with potential for strengthened market leadership. With renewed focus and disciplined execution, MC2 Therapeutics will intensify efforts to expand globally.
The transition to new leadership reflects a planned and strategic evolution of MC2 Therapeutics, aligned with the company’s focus on commercial expansion. The company extends its sincere thanks to Jesper J. Lange who has served as CEO of the company since inception. Under Jesper’s entrepreneurial leadership, MC2 Therapeutics has developed Wynzora® Cream, formed alliances with key partners in four continents and established commercial manufacturing with three CMOs across the EU and US to support global growth. Jesper hands over a mature company poised for its next phase of focused commercial execution and global growth for Wynzora® Cream.
About Wynzora® Cream
Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, in adults. It has a broad mode of action by targeting keratinocyte proliferation and differentiation and inhibiting expression of pro-inflammatory hallmark cytokines such as IL-23, IL-17A/F and TNF-α. Wynzora® Cream is uniquely enabled by MC2 Therapeutics’ formulation and drug delivery system PAD Technology™, allowing an effective convenient-to-use aqueous formulation. Wynzora® Cream was approved in the US by the FDA on July 20th, 2020, and in the first country in Europe on July 9th, 2021 (Link).
About MC2 Therapeutics A/S
MC2 Therapeutics is a private pharmaceutical company dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. The company is dedicated to improving the lives of people with plaque psoriasis and inflamed dry and itchy skin through innovative and effective therapies and support. Its marketed flagship drug Wynzora® Cream is partnered with leading pharmaceutical companies specialized in dermatology in more than 40 countries in four continents. The company is based in Hørsholm, Denmark and in Guildford, United Kingdom.
Contact
MC2 Therapeutics A/S
Lonni Goltermann
+45 2018 1111
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Leadership; Appointments and Schedules; Psoriasis; Betamethasone; Drug Delivery Systems; MC2 Therapeutics; Trine Ahlgreen; CEO; Wynzora® Cream; PAD Technology™; topical therapies; inflammatory skin conditions; plaque psoriasis; drug delivery system; formulation platform; dermatology; chronic dermatologic conditions; calcipotriene; betamethasone dipropionate; keratinocyte proliferation; aqueous formulation; FDA approval; pharmaceutical partnerships; Hørsholm; Denmark; Guildford; United Kingdom
Source: Biotech Newswire